GDP — Good Distribution Practice

GDP (Good Distribution Practice) is the EU guideline for proper distribution of human medicinal products (2013/C 343/01). It binds pharmaceutical wholesalers to continuous temperature monitoring, audit trail, documented validation and qualification of the entire distribution process. GDP scope covers goods receipt, storage, picking, dispatch and returns — with mandatory traceability and IT-system validation under CSV/GAMP-5 frameworks.

Core GDP requirements

• Temperature monitoring in warehouse and during transport (continuous, documented)
• Validation of all IT systems (Computerised System Validation, GAMP-5)
• Audit trail for every regulated booking
• Qualification documents (IQ/OQ/PQ)
• Training records for staff
• Authorisation segregation operations vs quality
• Complaint and recall processes
• Supplier auditing

GDP in the ERP context

A GDP-compliant ERP must implement these requirements natively — retrofitted custom solutions are expensive in audits. Pharma-specialist platforms like SAP S/4HANA Pharma, NovaTec Pharma, Greco-Software bring GDP workflows in standard. Generic ERPs require a certified add-on and deep validation. See also the glossary entry on GxP Validation for the underlying compliance framework.

Relation to Securpharm and FMD

GDP complements the EU Falsified Medicines Directive (FMD). While FMD/Securpharm governs the code-verification workflow, GDP regulates operational distribution. For pharmaceutical wholesalers in Germany, Switzerland and Austria, both compliance dimensions are mandatory.

ERP selection criteria for GDP-regulated operations

For DACH pharmaceutical wholesalers and 3PL providers in pharma, a procurement shortlist should include the following capabilities as hard requirements. Temperature data ingestion: native integration with sensor networks (Berlinger, ELPRO, Testo Saveris) and a tamper-evident time-series store for the temperature history of each batch. Lot- and serial-level traceability: bidirectional traceability from inbound goods receipt through picking and dispatch back to the supplier, mapped to the German audit trail requirement. Securpharm/FMD verification: connection to the German NMVO (National Medicines Verification Organisation) and automated decommissioning at the point of dispense or export. Recall workflow: a structured market-action process that identifies affected stock within minutes, blocks further movement and produces the regulatory notification dossier. Validation-friendly architecture: vendor-supplied IQ/OQ documentation templates, change-control workflows, and qualified upgrade procedures that minimise re-validation effort on each release. Implementation budgets in the German pharma wholesale market typically range 800,000 to 4 million EUR for the first GDP-validated ERP rollout, depending on warehouse count and degree of automation.

Practical examples and integration patterns

Three illustrative patterns from the DACH mid-market. Regional pharma wholesaler (single warehouse, 20,000 SKUs, 50 employees): SAP S/4HANA Pharma with bolt-on temperature monitoring from ELPRO and Securpharm verification via a national-system gateway. Total project around 1.2 million EUR, 14 months implementation. Clinical-trial logistics specialist (multi-site, temperature-controlled): NovaTec Pharma with custom integration to a courier-management platform and CMR digital-signature workflow. Initial validation runs 200 person-days. Veterinary-pharma distributor (Switzerland and Austria, 8,000 SKUs): Greco-Software with simplified GDP processes given the lower regulatory pressure on veterinary versus human pharma. Across all three patterns, the typical integration list includes the DATEV interface for accounting, a WMS for picking-route optimisation, and a transport-management system for cold-chain courier dispatch. Quality-management documents flow into a separate validated DMS rather than the ERP. The GDP-relevant master data — suppliers, transport routes, temperature thresholds per item — lives in the ERP with replication to the WMS, never the reverse.

Audit preparation and inspection practice

GDP inspections in the DACH region are conducted by regional regulatory authorities: the Bezirksregierungen and Länderbehörden in Germany, Swissmedic in Switzerland, the BASG in Austria. A typical inspection runs three to five days on site, with a follow-up written report and CAPA (Corrective and Preventive Action) plan due within 30 to 60 days. Areas of focus consistently include: (1) temperature-mapping documentation for warehouse zones and refrigerated transport, (2) batch-traceability test extractions through the ERP and WMS, (3) deviation-handling and complaint-recording workflows, (4) supplier-qualification records including audit reports for the company's own suppliers, (5) training records for all staff with GDP-relevant responsibilities, (6) IT-validation evidence for the ERP and any integrated systems. ERP-side preparation includes producing a Validation Master Plan summary, current IQ/OQ/PQ artefacts, change-control records since the last inspection, periodic-review reports, and a list of all GxP-impact assessments. Mid-market pharma wholesalers in DACH typically prepare for inspection through a mock-inspection exercise 4–8 weeks ahead, with an external GDP consultant playing the inspector role. Findings from prior inspections inform the focus areas of the next round. Repeat findings on the same item are a major red flag and may trigger a critical finding with operational consequences (suspension of distribution authorisation in severe cases). Sustained GDP excellence rests on three operational practices: continuous documentation discipline (not a pre-inspection sprint), regular internal audits by qualified personnel independent of operations, and active engagement with industry associations such as PHAGRO and Phagro Schweiz that share regulatory updates and inspection trends.

Related Topics

• GxP Validation
• Audit trail